EHA Unplugged

Listen as Prof. Christian Chabannon from Aix Marseille Université in France who tells about GoCART Coalition in this new podcast episode. The main goal of this coalition, which unites expertise from many fields, is to promote access to novel cellular therapies, such as CAR T-cells. Prof. Chabannon explain how GoCART is working on reaching this goal by generating new clinical insights, improving st...

Jan Geissler from Germany tells about his work as a patient advocate in the field of hematological malignancies. As a cancer survivor, patient advocate and patient engagement expert, Jan has been working tirelessly for many years in organizations such as European Patients Academy (EUPATI), Patvocates and many others. Listen to Jan’s passionate call for a collaborative spirit to achieve the best ou...

Prof. Maria Themeli tells about most recent developments in the field of “off-the-shelf” CAR T-cells. As the clinical success of advanced cellular therapies is growing, so is the need for broader access to these treatments. Listen as Prof. Themeli summarize the state-of-the-art technology that aims to generate “off-the-shelf” CAR T-cells from sources such as induced pluripotent stem cells (iPSCs)...

Join dr. Carmen Sanges from University Clinic Würzburg in Germany as she tells us about AIDPATH. This collaborative initiative is dedicated to improving access to advanced cellular therapies by employing artificial intelligence (AI) in the production process. Listen to dr. Sanges explain how AI technology is used to integrate patient-specific information and biomarkers to optimize CAR-T therapy. T...

Join us for this inspiring interview with prof. Elizabeth Macintyre from Université Paris Cité in France who tells us about her professional journey in hematology. Listen to prof. Macintyre discuss her views on the current state and future directions of advanced diagnostics in malignant hematology and their implications for healthcare management and the training of young specialists. Tune in to he...

Join Professor Kirsten Gronbaek and Professor Uwe Platzbecker as they discuss the complexities behind the classification and prognostication of low-risk myelodysplastic syndromes (MDS). They dive into the historical context of MDS classification, the evolution of prognostic indexes such as IPSS and IPSSM, and the implications of recent molecular findings.   This conversation highlights the challen...

Join host Professor Kirsten Gronbaek and guest Professor Arjan van de Loosdrecht as they dive into the complexities of measurable residual disease (MRD) monitoring in myelodysplastic syndromes (MDS) and myeloid cancers. Professor van de Loosdrecht explains the transition from minimal to measurable residual disease, the significance of MRD in predicting disease outcomes, and the various techniques...

In this episode, we sit down with prof. Martin Dreyling from the Ludwig-Maximilians-University in Munich who talks about his professional journey in hematology as a clinician and a researcher. Listen to prof. Dreyling as he recalls his contributions to the field of lymphoma, and in particular mantle cell lymphoma, that resulted in novel therapeutic approaches. The ongoing emphasis on the cross-bor...

In this episode, prof. Kirsten Gronbaek and dr. Shahram Kordasti discuss the role of immune dysfunction in MDS. With the improving understanding of complex pathophysiology of MDS, the major role of the immune system in this process is becoming increasingly apparent. Listen to dr. Kordasti discuss the multifactorial interactions between the malignant clones and the inflammatory environment, manifes...

In this interview, dr. Maria del Mar Mañu Pereira from Vall d’Hebron Research Institute in Spain talks about the Rare Anemia Disorders European Epidemiological Platform (RADeep). RADeep is an initiative of ERN-EuroBloodNet and functions as an umbrella for both new and already existing European patients' registries in rare anemia disorders.   Listen to dr. Mañu Pereira talk about the history of RAD...

Prof. Antonio Almeida from Hospital da Luz in Lisbon takes us through his professional journey in hematology as a clinician and educator, and his current role as the President of EHA. Listen to prof. Almeida recount his professional path that allowed him to experience various facets of hematological clinical practice in the UK and Portugal. Alongside his career as a hematologist, prof. Almeida cul...

Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options. He uses the example of targeting NLRP3/IL-1...

Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be add...

In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic p...

Join us for this insightful interview with prof. Brian Huntly from the University of Cambridge who tells about his professional journey in hematology as a clinician, scientist and educator. Listen to prof. Huntly discuss his important contributions to the field of leukemia stem cell biology in the context of current understanding of cell biological hierarchies and leukemia development. Prof. Huntl...

In this podcast, Prof Dame Lesley Fallowfield and Prof Clemens Wendtner discuss patient mental health and communication in the context of Chronic Lymphocytic Leukemia (CLL) treatment. They explore the psychological impact of CLL and leukemia in general, the importance of patient communication, and the need for integrated mental health support.  The conversation highlights the challenges of explain...

Join us for an insightful interview with patient advocates Miriam Santos Freire (sickle cell disease) and Loris Brunetta (beta-thalassemia major). Benefit from their experiences as they discuss with our host Isabel Olivera-Martinez the promises and challenges of gene therapy for these conditions. Listen to their experiences of living with these genetic conditions while they highlight the dispariti...

Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice. Prof Stamatopoulos descr...

This podcast episode is derived from the MDS Algorithm on EHA Campus . Check out the MDS Algorithm, which is an expert based tool for healthcare providers, ensuring a structured and evidence-based approach to managing myelodysplastic syndromes. In this episode, our host Prof Kirsten Grønbæk from University of Copenhagen, discusses the management of high-risk MDS with Prof Katharina Götze from Tech...

In this episode on recent insights about metabolism of the hematopoietic stem cells (HSCs), Dr Krzysztof Szade from Jagellonian University in Krakow, Poland, discusses HSPc in health, aging and malignancy. This podcast recaps the findings that aim to elucidate the metabolic requirements of HSCs at different stages of aging. Listen to Dr Szade summarize the data on how heme oxygenase-1 (HO-1) influ...

This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic. As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to thin...

As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same fami...

In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients. Thank...

In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS. The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to...

In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence. As for other hematological diseases, treatment of PCNSL...